Vivek Podder, MBBS
@VPodder
Followers
53
Following
55
Statuses
104
Physician⏐ Postdoctoral Researcher ⏐ Author of First Aid for the USMLE Step 1 ⏐ Medical Editor ⏐ Patient Advocate
Miami, FL
Joined December 2017
RT @oncodaily: Endocrine Treatments for Patients Diagnosed with Endometrial Cancer in 2025 - @VPodder
#Health #M…
0
2
0
RT @NEJMEvidence: How do we make sense of two “negative” trials in @NEJM and a “positive” meta-analysis of the two trials in NEJM Evidence?…
0
282
0
RT @DrYukselUrun: 🧬🩸Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy (ctDNA), addressing l…
0
70
0
RT @ErikaHamilton9: Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review. First line CDK 2nd line profile driven ADC/…
0
60
0
RT @VivekSubbiah: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive…
0
10
0
RT @Cancers_MDPI: 🤔How safe are #ICIs for brain metastases? 💡Our new Cancers review explores irAEs, neurotoxicity, and combination strategi…
0
1
0
RT @AaronGoodman33: We spend so much money answering useless research questions. I wish more money was directed at studies addressing de-e…
0
54
0
RT @oncodaily: Our latest selected abstracts presented at SNO2024 - @VPodder
@BrainTumorDoc
#Cancer #OncoDaily…
0
1
0
RT @JAMA_current: The USPSTF latest guidelines on screening for breast cancer recommends that all women undergo routine screening every oth…
0
18
0
RT @VPrasadMDMPH: Systematic Reviews - An Introduction - 4 mistakes people make - How to Search
0
34
0
RT @TargetedOnc: WATCH: Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast can…
0
4
0
Our article on ICIs in treating BM from NSCLC, showcasing their efficacy as single/double agents or combined with other therapies, is now published in Cancers! Proud to work with DrRanjan @kmargolin DrVelcheti, DrArun Maharaj @BrainTumorDoc
0
0
4
RT @PTarantinoMD: ADCs are among the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved and >200 in active deve…
0
71
0
RT @drsarahsam: We should try this either as primary or secondary prevention for T-Dxd pneumonitis… @PTarantinoMD
0
8
0
RT @DFCI_BreastOnc: 📰Check out this recently published phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for #CentralNe…
0
9
0
0
12
0
RT @stolaney1: ESG401 (TROP2 ADC, linked to SN-38) Trial in HER2-neg brain mets n=21 iORR 41& ORR 53% Median PFS 4.6 mo Common AEs: Leukop…
0
9
0
RT @stolaney1: DAISY No correlation between spatial HER2 + benefit No significant change in CD8 lymphocytes No genomic alterations assoc…
0
18
0